Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Immuneering Corporation (NASDAQ:IMRX), that sends out a positive message to the company's shareholders.

While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

View our latest analysis for Immuneering

Immuneering Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider purchase was by Director Peter Feinberg for US$183k worth of shares, at about US$3.05 per share. That means that even when the share price was higher than US$1.13 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. To us, it's very important to consider the price insiders pay for shares. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.

While Immuneering insiders bought shares during the last year, they didn't sell. The average buy price was around US$2.43. These transactions suggest that insiders have considered the current price attractive. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership

Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 29% of Immuneering shares, worth about US$10m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Do The Immuneering Insider Transactions Indicate?

It doesn't really mean much that no insider has traded Immuneering shares in the last quarter. However, our analysis of transactions over the last year is heartening. Insiders own shares in Immuneering and we see no evidence to suggest they are worried about the future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Our analysis shows 6 warning signs for Immuneering (3 don't sit too well with us!) and we strongly recommend you look at them before investing.